Durvalumab and tremelimumab with or without lenvatinib in combination with concurrent transarterial chemoembolisation in patients with locoregional hepatocellular carcinoma

Durvalumab and tremelimumab with or without lenvatinib in combination with concurrent transarterial chemoembolisation are in clinical development for the treatment of adults with hepatocellular carcinoma (HCC). HCC is a primary cancer arising from hepatocytes in predominantly cirrhotic liver. However, some patients may not have cirrhosis before developing HCC, especially those with chronic hepatitis B virus. A significant number of patients may be asymptomatic and are diagnosed following screening. Symptoms of HCC can include: the whites of eyes turning yellow or skin turning yellow, loss of appetite or losing weight without trying to, feeling tired, feeling generally unwell or having symptoms like flu, a lump in the right side of tummy, and symptoms of indigestion. Current treatment options may include surgery, chemotherapy, using heat to destroy the cancer (thermal ablation), targeted medicines, and radiotherapy. There is need for more treatment options with more efficacy because the current treatment options are limited.